FDA Approved: SAJAZIR — Supplemental Application (Cycle Pharmaceuticals Ltd-Uk)

View source ↗

Summary

SAJAZIR (icatibant) received FDA approval of a supplemental application filed by Cycle Pharmaceuticals Ltd-Uk.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Angioedema

Drugs mentioned

• SAJAZIR (icatibant)

Snippet

SUPPL AP for SAJAZIR (ICATIBANT)